Freeline Therapeutics Holdings plc logo
Freeline Therapeutics Holdings plc FRLN
$ 6.48 0.0%

Annual report 2022
added 12-21-2024

report update icon

Freeline Therapeutics Holdings plc Financial Statements 2011-2024 | FRLN

Annual Financial Statements Freeline Therapeutics Holdings plc

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

261 M 44.3 M 255 M 40.1 M 20.3 M - - - - - - -

Shares

59.3 M 35.7 M 14.2 M 6.35 M 4.62 M - - - - - - -

Historical Prices

4.4 1.24 18 - - - - - - - - -

Net Income

-89 M -140 M -96.3 M -53.9 M -33.3 M - - - - - - -

Revenue

- - - - - - - - - - - -

Cost of Revenue

- - - - - - - - - - - -

Gross Profit

- - - - - - - - - - - -

Operating Income

-98.4 M -142 M -102 M -63.6 M -41 M - - - - - - -

Interest Expense

- -165 K -9.29 M -793 K 7.72 M - - - - - - -

EBITDA

-96.7 M -140 M -101 M -62.1 M -40 M - - - - - - -

Operating Expenses

- 142 M - 63.6 M 41 M - - - - - - -

General and Administrative Expenses

- 44.6 M 26.3 M 16.6 M 6.79 M - - - - - - -

All numbers in USD currency

Quarterly Income Statement Freeline Therapeutics Holdings plc

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

- - - 42.6 M 35.9 M 35.8 M 35.8 M 35.7 M 35.9 M - 11.9 M 9.01 M 12 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

- - - -26.7 M - - - -34.9 M - - - -16.7 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

- - - -28.2 M - - - -33.9 M - - - -21.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

- - - 990 K - - - -1.73 M - - - 863 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

- - - -27.6 M - - - -33.4 M - - - -20.7 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

- - - 28.2 M - - - 33.9 M - - - 21.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

- - - 8.22 M - - - 10.1 M - - - 3.74 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency